Spackman Equities Group Inc. (TSXV: SQG) (the "Company" or "SEGI") has entered into an advisory agreement (the "Agreement") ...

Breast Tumor Section showing nonamplified HER-2/neu (<4 signals/nucleus). Cells are stained with DAPI. Probe is detected with flurorescein. There is perhaps nothing more disturbing to a woman than a ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

and human epidermal growth factor receptor 2 (HER2/neu)—that targeted medications act upon to reduce tumor growth. Even when initial treatment leads to remission, the chance of triple-negative ...

Roche has received FDA approval for a label expansion of its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which identifies patients with HR–positive, HER2-ultralow metastatic ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 These patients may now ...

In close collaboration with the lab of Nai-Kong Cheung at MSK and Dane Wittrup at MIT, we have successfully applied this platform in three preclinical tumor models: GPA33 antigen (colorectal cancer); ...

“Now it is approved for lung cancer, gynecological cancers, biliary tract cancers – any type of cancer which expresses a target in the cancer cells called HER2-positive.” If your doctor has ...

The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test is used with Roche’s fully automated BenchMark IHC/ISH slide-staining instrument.

BMBC is common in patients negative for estrogen/progesterone receptors and over-expressing epidermal growth factor receptor1 or 2 (EGFR or HER2/neu). However, both traditional and recent therapies ...